(1) Objectives: Rhinoplastic surgery is one of the biggest challenges with manipulation or surgery to improve the cosmetic and functional nasal form. Tranexamic acid, is a competitive inhibitor of plasminogen activator in much higher concentrations is a non- competitive inhibitor of plasmin. In rhinoplastic surgery the amount of blood loss during surgery can be controlled in different ways, including the implementation of intraoperative controlled hypotension as well as the use of anti-fibrinolytic drugs such as tranexamic acid before, during, or after operation. Intraveneous tranexamic acid during surgical procedures are used. So far, studies on the use of pre-operative oral tranexamic acid on bleeding during rhinoplastic surgery hasn’t been performed in adults.
(2) Design: This study is a randomized, double-blind clinical trial study to evaluate the effects of preoperative oral tranexamic acid in adults candidated for rhinoplastic surgery for reducing blood loss in Shiraz Chamran Hospital. A total of 50 adult patients between the ages of 16 to 40 years were randomized to receive either oral tanexamic acid group and the placebo group assigned anesthesiologist, while the doctor, a student of project manager, will be unaware. After obtaining informed consent from the patient, 2 hours before surgery, by maxillofacial ward nurse's a 1,000 mg (two 500 mg tranexamic acid tablets orally) with about 20 cc of water 2 hours before surgery. (3) Setting and conduct: A questionnaire that included demographic information (age , sex and weight ) - Medical History - Hemodynamic values recorded before, during and after operation, duration of surgery and the amount of intraoperative bleeding will be recorded. Bleeding with surgical weight Gauzes is calculated using a digital scale in the operating room, so that bloody Gauzes secured with Beex box to prevent evaporation. At the end of the operation is determined by the amount of blood in the suction device that is added to the total amount of intraoperative bleeding.
(4) Participants including major eligibility criteria: The patients with systemic disease and no history of drug use, and willingness to cooperate in this study are enrolled؛ Exclusion criteria included known allergy to the study drug, hepatic and renal dysfunction and lack of signed informed consent will be excluded.
(5) Intervention: Drug is administered with dose of 1000 mg (two 500 mg tablets) orally with about 20 cc of water are given to the patient's study 2 hours before surgery and the second group received placebo with about 20 cc of water patients.
(6) Main outcome measures: Hemodynamic values is recorded before, during and post-operative and amount of blood loss during surgery as well as surgical duration, the weight of Gauze is calculated using a digital scale in the operating room.